全膝关节置换术后联用非甾体抗炎药与直接口服抗凝药的风险获益特征
基于2010至2023年全国理赔数据库的回顾性队列研究,纳入接受初次全膝关节置换术(TKA)并使用直接口服抗凝药(DOAC)预防静脉血栓栓塞的患者,倾向性评分匹配后比较联用非甾体抗炎药(NSAID)与单用DOAC的结局。联用NSAID与伤口裂开、手术部位感染、假体周围感染及2年翻修风险升高相关,但关节纤维化及手法松解率降低,90天出血事件无差异。
要点
- TKA术后联用NSAID与DOAC增加伤口裂开、手术部位感染和假体周围感染风险。
- 联用NSAID与DOAC不增加90天出血事件,但2年翻修风险升高。
- 联用NSAID与DOAC降低关节纤维化及手法松解率,呈现临床权衡。
核心结论
- TKA术后联用NSAID与DOAC预防静脉血栓栓塞的患者,伤口并发症、感染及全因翻修率更高,但关节纤维化相关结局更低。
研究设计与样本
- 回顾性队列研究,使用2010至2023年全国理赔数据库,纳入初次TKA后接受DOAC预防至少3天的患者。
- 倾向性评分按1:3匹配联用NSAID组与单用DOAC组,匹配队列包括12,733例联用DOAC加NSAID患者和37,127例单用DOAC患者。
- 证据等级III级。
主要发现
- 联用NSAID与DOAC与伤口裂开风险升高相关(OR 1.49,95%CI 1.20至1.87)。
- 联用NSAID与DOAC与手术部位感染风险升高相关(OR 1.71,95%CI 1.25至2.34)。
- 联用NSAID与DOAC与假体周围感染风险升高相关(OR 1.24,95%CI 1.01至1.52)。
- 90天出血事件无差异(P > 0.05)。
- 2年随访时,联用NSAID与DOAC与翻修风险升高相关(OR 1.52,95%CI 1.13至2.05),但关节纤维化风险降低(OR 0.92,95%CI 0.86至0.98),手法松解率降低(OR 0.69,95%CI 0.62至0.77)。
关键数值与推荐
- 亚组分析显示塞来昔布与伤口裂开、手术部位感染及失血性贫血发生率升高相关。
- 亚组分析显示布洛芬与手术部位感染风险升高相关。
临床怎么用
- TKA术后联用NSAID与DOAC时需进行患者特异性风险分层,并谨慎选择NSAID。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Nonsteroidal anti-inflammatory drugs (NSAIDs) are commonly prescribed after total knee arthroplasty (TKA) for analgesia and inflammation control in conjunction with direct oral anticoagulants (DOACs) for venous thromboembolism prophylaxis in high-risk patients. In nonorthopaedic populations, concurrent NSAID-anticoagulant increases bleeding risk, but post-TKA safety data remain limited. METHODS: Using a national claims database (2010 to 2023), we identified patients undergoing primary TKA who received DOAC-only venous thromboembolism prophylaxis for ≥ three days. Patients coprescribed NSAIDs were propensity score-matched 1:3 to DOAC-only patients based on demographics, comorbidities, and preoperative anticoagulant use. The matched cohort included 12,733 patients who received DOAC plus NSAID therapy and 37,127 who received DOAC alone. Outcomes included 90-day medical and surgical complications, 2-year implant-related complications, and arthrofibrosis-associated outcomes. Subanalyses evaluated outcomes by NSAID type and prescription duration. RESULTS: Combination therapy was associated with increased wound dehiscence (odds ratio (OR) 1.49, 95% confidence interval 1.20 to 1.87), surgical site infection (OR 1.71 [1.25 to 2.34]), and periprosthetic joint infection (OR 1.24 [1.01 to 1.52]), without differences in 90-day bleeding events (P > 0.05). At 2 years, NSAID plus DOAC therapy was associated with higher revision risk (OR 1.52 [1.13 to 2.05]), but lower arthrofibrosis (OR 0.92 [0.86 to 0.98]) and manipulation under-anesthesia rates (OR 0.69 [0.62 to 0.77]). Subgroup analyses demonstrated that celecoxib was associated with higher rates of wound dehiscence, surgical site infection, and blood loss anemia, while ibuprofen was associated with an increased risk of surgical site infection. CONCLUSIONS: Patients who received concurrent NSAIDs with DOAC prophylaxis following TKA had higher rates of wound complications, infection, and all-cause revision, despite lower rates of arthrofibrosis-related outcomes. These findings demonstrate a clinically relevant trade-off and emphasize the importance of patient-specific risk stratification and cautious NSAID selection when used concurrently with DOAC therapy after TKA. LEVEL OF EVIDENCE: III (Retrospective Cohort Study).
引用
- Paul BR, Verhey JT, Haak GM, et al. Risk and Benefit Profile With Concurrent Nonsteroidal Anti-Inflammatory Drugs and Direct Oral Anticoagulants Following Total Knee Arthroplasty. J Arthroplasty. 2026. PMID: 42285321. doi:10.1016/j.arth.2026.06.016
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。